Tech Company Financing Transactions
Neurelis Funding Round
Cormorant Asset Management, Decheng Capital and HBM Healthcare Investments invested in a $114 million Series D funding round for Neurelis. The round was announced by the company on 3/12/2021.
Transaction Overview
Company Name
Announced On
3/12/2021
Transaction Type
Venture Equity
Amount
$114,000,000
Round
Series D
Investors
Proceeds Purpose
The company intends to use the funds to commercialize its lead orphan drug product, VALTOCO (diazepam nasal spray), and to continue the development and expansion of its neuroscience pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3430 Carmel Mountain Rd. 300
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Neurelis, Inc. is a specialty pharmaceutical company organized to license, develop, and commercialize product candidates for the treatment of central nervous system disorders with a focus on the treatment of acute breakthrough seizures (epilepsy) and acute anxiety episodes.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Craig Chambliss
Chief Financial Officer
George Stuart
Chief Medical Officer
Enrique Carrazana
Chief Scientific Officer
Stuart Madden
Vice President
Chuck DeWildt
Vice President
Adrian Rabinowicz
VP - Bus. Development
Thomas Liquard
VP - General Counsel
Jenny Alonso
VP - Marketing
Steve Jenner
VP - Regulatory Affairs
Edward Smith
Browse more venture capital transactions:
Prev: 3/12/2021: Pathlock venture capital transaction
Next: 3/12/2021: Icertis venture capital transaction
Share this article
Where The Data Comes From
We document all VC transactions involving tech companies. VC investment data records on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs